×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PTGX – protagonist therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PTGX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/10
05:18 pm
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Citigroup Inc. from $96.00 to $98.00. They now have a "buy" rating on the stock.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Citigroup Inc. from $96.00 to $98.00. They now have a "buy" rating on the stock.
11/7
03:46 pm
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at JPMorgan Chase & Co. from $68.00 to $81.00. They now have an "overweight" rating on the stock.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at JPMorgan Chase & Co. from $68.00 to $81.00. They now have an "overweight" rating on the stock.
11/7
11:09 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Barclays PLC from $72.00 to $88.00. They now have an "overweight" rating on the stock.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Barclays PLC from $72.00 to $88.00. They now have an "overweight" rating on the stock.
11/7
09:41 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Citizens Jmp from $69.00 to $102.00. They now have a "market outperform" rating on the stock.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Citizens Jmp from $69.00 to $102.00. They now have a "market outperform" rating on the stock.
11/4
05:38 pm
ptgx
Protagonist Therapeutics (PTGX): Valuation Insights Ahead of Key Rusfertide Clinical Data at ASH Meeting [Yahoo! Finance]
Low
Report
Protagonist Therapeutics (PTGX): Valuation Insights Ahead of Key Rusfertide Clinical Data at ASH Meeting [Yahoo! Finance]
10/28
10:58 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) was given a new $88.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) was given a new $88.00 price target on by analysts at Truist Financial Corporation.
10/28
09:14 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Wedbush from $70.00 to $86.00. They now have an "outperform" rating on the stock.
Medium
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Wedbush from $70.00 to $86.00. They now have an "outperform" rating on the stock.
10/28
08:09 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $82.00 price target on the stock.
Medium
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $82.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2025
04:05 pm
ptgx
protagonist therapeutics, inc.
MISS
Report
-0.3%
protagonist therapeutics, inc.
8/6/2025
04:05 pm
ptgx
protagonist therapeutics, inc.
MISS
Report
-5.4%
protagonist therapeutics, inc.
5/6/2025
04:05 pm
ptgx
protagonist therapeutics, inc.
BEAT
Report
2.6%
protagonist therapeutics, inc.
2/21/2025
07:00 am
ptgx
protagonist therapeutics, inc.
BEAT
Report
-0.8%
protagonist therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/24
04:01 pm
ptgx
Form 4 Protagonist Therapeutics For: Nov 21 Filed by: PATEL DINESH V PH D
Low
Report
Form 4 Protagonist Therapeutics For: Nov 21 Filed by: PATEL DINESH V PH D
11/19
04:01 pm
ptgx
Form 4 Protagonist Therapeutics For: Nov 17 Filed by: MOLINA ARTURO MD
Low
Report
Form 4 Protagonist Therapeutics For: Nov 17 Filed by: MOLINA ARTURO MD
11/14
04:24 pm
ptgx
Form SCHEDULE 13G/A Protagonist Therapeutics Filed by: BIOTECHNOLOGY VALUE FUND L P
Low
Report
Form SCHEDULE 13G/A Protagonist Therapeutics Filed by: BIOTECHNOLOGY VALUE FUND L P
11/14
08:23 am
ptgx
Form SCHEDULE 13G/A Protagonist Therapeutics Filed by: Deep Track Capital, LP
Low
Report
Form SCHEDULE 13G/A Protagonist Therapeutics Filed by: Deep Track Capital, LP
11/6
04:52 pm
ptgx
Form 10-Q Protagonist Therapeutics For: Sep 30
Low
Report
Form 10-Q Protagonist Therapeutics For: Sep 30
11/6
04:21 pm
ptgx
Form 8-K Protagonist Therapeutics For: Nov 06
Low
Report
Form 8-K Protagonist Therapeutics For: Nov 06
10/17
06:24 pm
ptgx
Form SCHEDULE 13G/A Protagonist Therapeutics Filed by: BlackRock, Inc.
Low
Report
Form SCHEDULE 13G/A Protagonist Therapeutics Filed by: BlackRock, Inc.
10/14
04:01 pm
ptgx
Form 4 Protagonist Therapeutics For: Oct 10 Filed by: Waddill William D.
Low
Report
Form 4 Protagonist Therapeutics For: Oct 10 Filed by: Waddill William D.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/3
Form 4 Protagonist Therapeutics For: Dec 03 Filed by: PATEL DINESH V PH D
70.0%
3/12 Form 4 Protagonist Therapeutics For: Mar 12 Filed by: SELICK HAROLD E 18.3%
5/8 Form 10-Q Protagonist Therapeutics For: Mar 31 16.7%
3/18 Form 8-K Protagonist Therapeutics For: Mar 13 10.9%
10/30 Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera 8.1%
8/17 Protagonist Therapeutics Inc (NASDAQ: PTGX) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 7.8%
9/25 Protagonist Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 2 7.1%
8/20 Protagonist Therapeutics Inc (NASDAQ: PTGX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 6.6%
5/8 Q1/2019 3/31/2019 EPS -0.580 ZacksConsensus -0.640 ActVsEst 0.060 - Beat 6.2%
11/9 Protagonist Therapeutics Inc (NASDAQ: PTGX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 4.3%
3/12 Form 4 Protagonist Therapeutics For: Mar 12 Filed by: SELICK HAROLD E 18.3%
5/8 Form 10-Q Protagonist Therapeutics For: Mar 31 16.7%
3/18 Form 8-K Protagonist Therapeutics For: Mar 13 10.9%
10/30 Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera 8.1%
8/17 Protagonist Therapeutics Inc (NASDAQ: PTGX) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 7.8%
9/25 Protagonist Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 2 7.1%
8/20 Protagonist Therapeutics Inc (NASDAQ: PTGX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 6.6%
5/8 Q1/2019 3/31/2019 EPS -0.580 ZacksConsensus -0.640 ActVsEst 0.060 - Beat 6.2%
11/9 Protagonist Therapeutics Inc (NASDAQ: PTGX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 4.3%
TOP News Decliners
12/3
Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia
-46.7%
11/6 Form 10-Q Protagonist Therapeutics For: Sep 30 -14.4%
11/25 Form EFFECT Protagonist Therapeutics -11.9%
5/7 Protagonist Therapeutics to Present Preclinical Data on PN-943 at Digestive Disease Week Conference 2019 -11.1%
11/26 Protagonist's Upcoming Catalyst Has The Potential To Carve Out A Solid Path With Lead Drug [Seeking Alpha] -7.7%
3/6 Protagonist Therapeutics Inc (NASDAQ: PTGX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -7.3%
3/12 Protagonist Therapeutics Inc (NASDAQ: PTGX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.50 price target on the stock. -6.7%
3/10 Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.2%
11/6 Protagonist Therapeutics Inc (NASDAQ: PTGX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.8%
7/25 Protagonist Therapeutics Inc (NASDAQ: PTGX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -4.7%
11/6 Form 10-Q Protagonist Therapeutics For: Sep 30 -14.4%
11/25 Form EFFECT Protagonist Therapeutics -11.9%
5/7 Protagonist Therapeutics to Present Preclinical Data on PN-943 at Digestive Disease Week Conference 2019 -11.1%
11/26 Protagonist's Upcoming Catalyst Has The Potential To Carve Out A Solid Path With Lead Drug [Seeking Alpha] -7.7%
3/6 Protagonist Therapeutics Inc (NASDAQ: PTGX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -7.3%
3/12 Protagonist Therapeutics Inc (NASDAQ: PTGX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.50 price target on the stock. -6.7%
3/10 Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.2%
11/6 Protagonist Therapeutics Inc (NASDAQ: PTGX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.8%
7/25 Protagonist Therapeutics Inc (NASDAQ: PTGX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -4.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: